Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point
Date:12/11/2008

NEW YORK, Dec. 11 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH), a medical technology company testing its proprietary Percutaneous Hepatic Perfusion ("PHP") System for the treatment of cancers of the liver, announced today that the first fifty percent (46 of 92) of patients have been enrolled in the Phase III clinical trial treating metastatic cutaneous and ocular melanoma to the liver. The eleven participating cancer centers in this trial continue to evaluate and enroll patients and the Company looks forward to completing enrollment in 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO )

Commenting on this important event, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, "Enrollment of the forty-sixth patient in this trial represents a significant milestone for our Company as we continue to accelerate this trial and accrue the data to support FDA approval of the Delcath PHP System. Attaining the midpoint of this trial, on the heels of expanding to eleven centers, is an important confirmation that the Company remains on the clinical and regulatory schedule discussed with investors over the past six months. The clinical data for the first 46 patients will be submitted to the Data Safety Monitoring Board for evaluation, once we complete the collection of follow-up data on the recently treated patients. We look forward to updating our investors during our upcoming conference call to be held next month."

This multi-center clinical study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under this CRADA, patients for this study are being treated at the NCI and at ten cancer centers
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
4. Human Genome Sciences Completes Enrollment Ahead of Schedule in Second Phase 3 Albuferon(R) Trial
5. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
6. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
7. AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
8. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
9. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... May 22, 2013 Industry leaders ... VA for the Oak Ridge National Laboratory’s ... take place at the Hilton Alexandria Mark Center. ... Technologies 2013 conference on June 18 - ... , AdSave, American Elements, Applied Research Associates, ARA, ...
(Date:5/22/2013)... 2013 The Conference Forum ... to Advance Clinical Trials conference taking place on September ... MA. , Disruptive thinkers from Novartis, Pfizer, Eli ... bold approaches to reduce expensive infrastructure, engage patients and ... to be big, or novel, or it must change ...
(Date:5/22/2013)... May 22, 2013  Superior Controls, Inc. has ... by Business NH Magazine.  For the past 22 ... that distinguish themselves with extraordinary business and civic ... receive this honor," said Rick Pierro ... any recognition, this award is a reflection of ...
(Date:5/22/2013)... , May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: ... at the Second Annual Marcum LLP Microcap Conference, May 30, ... Neil Lyons , CPA, Chief Financial ... biodefense programs on May 30 at 1:30 p.m. Eastern Time.  ... be available on the Investors page of the Cleveland BioLabs ...
Breaking Biology Technology:Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 2Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 3Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 4Biodetection Technologies 2013 and Oak Ridge National Lab’s Biosurveillance Symposium to Bring Together Leading Organizations in Alexandria, VA from June 17-19, 2013 5Disruptive Innovation Hits Clinical Trials, Dedicated Event Launches 2Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2
... XEN-D0103, a potent and selective Kv1.5 antagonist, is safe ... LTD, the Cambridge-based biopharmaceutical company specialising in the discovery ... today from a phase 1 trial of XEN-D0103 administered ... potassium channel Kv1.5, was well tolerated and demonstrated good ...
... SAN DIEGO, March 19, 2012   Organovo Holdings, Inc. ... of an oversubscribed $15.2 million private placement. At the ... million through the sale of 6.9 million Units, at ... Post-closing Organovo has approximately 43.7 million shares of common ...
... such tests on samples sent in from all over Spain. ... truly personalised medicine. And researchers are exploring new ways to ... scale: the genes that are being read or transcribed; the ... the length of the telomeres capping its chromosomes. The ...
Cached Biology Technology:Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug 2Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug 3Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3CNIO researchers take part in the most comprehensive personalized medicine study performed to date 2CNIO researchers take part in the most comprehensive personalized medicine study performed to date 3
(Date:5/22/2013)... join together in a major new effort to educate ... providing Earth,s people with clean water that looms ahead ... comment article in the current edition of Chemical ... American Chemical Society (ACS), the world,s largest scientific society. ... and Jerald L. Schnoor, Ph.D., explain that shortages of ...
(Date:5/22/2013)... Adventitious changes in cellular DNA can endanger the whole ... cancer. Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich now report ... the double helix. , The DNA in our cells ... in our bodies. The instructions for this are encoded ... in DNA, the bases adenine (A), cytosine (C), guanine ...
(Date:5/22/2013)... pollinating insects and wild plants have slowed in recent ... by the University of Leeds and the Naturalis Biodiversity ... reductions in the diversity of species in Britain, Belgium ... But the picture brightened markedly after 1990, with a ... hoverflies and wild plants. , Professor Bill ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3
... helped produce a new archaeological tool which could answer ... curve, which extends back 50,000 years is a major ... and geoscientists to establish the age of carbon-based materials. ... of climate change on human adaption and migrations. ...
... WALNUT CREEK, CAAs the U.S. Department of Energy ... energy, perennial grasses have emerged as major candidates for ... little is known about the specific biological traits of ... energy production, in part because such grasses typically have ...
... make some hearts flutter on Valentine,s Day, but in ... designed to do just the opposite. , The nanoparticles ... created in the laboratory of SUNY Distinguished Professor and ... who developed the lithium/silver vanadium oxide battery. The battery ...
Cached Biology News:Queen's helps produce archaeological 'time machine' 2First wild grass species and model system for energy crops sequenced 2First wild grass species and model system for energy crops sequenced 3Silver nanoparticles may one day be key to devices that keep hearts beating strong and steady 2